A randomized, double-blind study comparing the safety and efficacy of clopidogrel versus ticlopidine in Japanese patients with noncardioembolic cerebral infarction

Cerebrovascular Diseases

Volumn 25, Issue 1-2, 2008, Pages 40-49

  Fukuuchi, Yasuo ^a   Tohgi, Hideo ^b   Okudera, Toshio ^c   Ikeda, Yasuo ^d   Miyanaga, Yoshitaka ^e   Uchiyama, Shinichiro ^e   Hirano, Masanori ^f   Shinohara, Yukito ^g   Matsumoto, Masayasu ^h   Yamaguchi, Takenori ⁱ  

^a ASHIKAGA RED CROSS HOSPITAL   (Japan)

^b Sobu Hospital   (Japan)

^c Shinfunagoya Hospital   (Japan)

^d KEIO UNIVERSITY   (Japan)

^e TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^f TOKYO METROPOLITAN POLICE HOSPITAL   (Japan)

^g Federation of National Public Service Personnel Mutual Aid Associations   (Japan)

^h HIROSHIMA UNIVERSITY   (Japan)

ⁱ NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

Author keywords

Clopidogrel; Ischemic stroke; Ticlopidine

Indexed keywords

CLOPIDOGREL; TICLOPIDINE;

ACUTE KIDNEY FAILURE; ADULT; AGED; ANOREXIA; ARTICLE; BRAIN HEMORRHAGE; BRAIN INFARCTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DUODENUM ULCER; EPISTAXIS; FEMALE; GAMMA ALANINE AMINOTRANSFERASE; GASTRITIS; HUMAN; INTRAOCULAR HEMORRHAGE; JAUNDICE; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MELENA; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; NEUTROPENIA; PLEURA EFFUSION; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; STOMACH HEMORRHAGE; STOMACH ULCER; THROMBOCYTOPENIA; UNIVARIATE ANALYSIS;

AGED; CEREBRAL INFARCTION; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; FEMALE; HUMANS; JAPAN; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; TICLOPIDINE; TREATMENT OUTCOME;

EID: 39549100344     PISSN: 10159770     EISSN: None     Source Type: Journal    
DOI: 10.1159/000111498     Document Type: Article

References (20)

1. Kubo M, Kiyohara Y, Kato I, Tanizaki Y, Arima H, Tanaka K, Nakamura H, Okubo K, Iida M: Trends in the incidence, mortality, and survival rate of cardiovascular disease in a Japanese community. The Hisayama Study. Stroke 2003;34:2349-2354.
2. Statistics and Information Department, Ministry of Health, Labour and Welfare, Japanese Government: Abridged Life Tables for Japan 2005. www.mhlw.go.jp. Last accessed November 10, 2006.
3. Hier DB, Foulkes MA, Swiontoniowski M, Sacco RL, Gorelick PB, Mohr JP, Price TR, Wolf PA: Stroke recurrence within 2 years after ischemic infarction. Stroke 1991;22:155-161.
4. Uchiyama S, Nakamura T, Yamazaki M, Kimura Y, Iwata M: New modalities and aspects of antiplatelet therapy for stroke prevention. Cerebrovasc Dis 2006;21(suppl 1):7-16.
5. The Joint Committee on Guidelines for the Management of Stroke: Japanese Guidelines for the Management of Stroke (in Japanese). Tokyo, Kyowa Kikaku, 2004.
6. Shinohara Y: Regional differences in incidence and management of stroke - is there any difference between Western and Japanese guidelines on antiplatelet therapy? Cerebrovasc Dis 2006;21(suppl 1):17-24.
7. Yamazaki T, Goto S, Shigematsu H, Shimada K, Uchiyama S, Nagai R, Yamada N, Matsumoto M, Origasa H, Ikeda Y; REACH Registry Investigators: Prevalence, awareness, and treatment of cardiovascular risk factors in patients at high risk of atherothrombosis in Japan. Circ J 2007;71:995-1003.
8. Hass WK, Easton JD, Adams HP Jr, Pryse-Phillips W, Molony BA, Anderson S, Kamm B: A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. N Engl J Med 1989;321:501-507.
9. Caplan LR: Antiplatelet therapy in stroke prevention: present and future. Cerebrovasc Dis 2006;21(suppl 1):1-6.
10. Bennett CL, Davidson CJ, Raisch DW, Weinberg PD, Bennett RH, Feldman MD: Thrombotic thrombocytopenic purpura associated with ticlopidine in the setting of coronary artery stents and stroke prevention. Arch Intern Med 1999;159:2524-2528.
11. CAPRIE Steering Committee: A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996;348:1329-1339.
12. Hirata K, Takagi H, Yamamoto M, Matsumoto T, Nishiya T, Mori K, Shimizu S, Masumoto H, Okutani Y: Ticlopidine-induced hepatotoxicity is associated with specific human leukocyte antigen genomic subtypes in Japanese patients: a preliminary case-control study. Pharmacogenomics J 2007, Epub ahead of print, DOI:10.1038/sj.tpj.6500442.
13. Harker LA, Boissel JP, Pilgrim AJ, Gent M, on behalf of the CAPRIE Steering Committee and Investigators: comparative safety and tolerability of clopidogrel and aspirin. Drug Saf 1999;21:325-335.
14. Zakarija A, Bandarenko N, Pandey DK, Auerbach A, Raisch DW, Kim B, Kwaan HC, McKoy JM, Schmitt BP, Davidson CJ, Yarnold PR, Gorelick PB, Bennett CL: Clopidogrel-associated TTP: an update of pharmacovigilance efforts conducted by indepen - dent researchers, pharmaceutical suppliers, and the Food and Drug Administration. Stroke 2004;35:533-537.
15. Plavix (Sanofi-Aventis Bristol-Myers Squibb SNC), Summary of Product Characteristics. http://emc.medicines.org.uk/emc/industry/default.asp?page= displaydoc.asp&documentid=9484. Last accessed January 16, 2007.
16. Bennett CL, Connors JM, Carwile JM, Moake JL, Bell WR, Tarantolo SR, McCarthy LJ, Sarode R, Hatfield AJ, Feldman MD, Davidson CJ, Tsai HM: Thrombotic thrombocytopenic purpura associated with clopidogrel. N Engl J Med 2000;342:1773-1777.
17. Gotoh F, Tohgi H, Hirai S, Terashi A, Fukuuchi Y, Otomo E, Shinohara Y, Itoh E, Matsuda T, Sawada T, Yamaguchi T, Nishimaru K, Ohashi Y: Cilostazol Stroke Prevention Study: a placebo-controlled double-blind trial for secondary prevention of cerebral infarction. J Stroke Cerebrovasc Dis 2000;9:147-157.
18. Bezerra DC, Bogousslavsky J: Antiplatelets in stroke prevention: the MATCH trial. Some answers, many questions and countless perspectives. Cerebrovasc Dis 2005;20(suppl 2):109-118.
19. Tanahashi N: Treatment of acute-stage lacunar infarction and prevention of recurrence. Jpn J Stroke 1995;17:571-577.
20. Steg PG, Bhatt DL, Wilson PW, D'Agostino R Sr, Ohman EM, Röther J, Liau CS, Hirsch AT, Mas JL, Ikeda Y, Pencina MJ, Goto S; REACH Registry Investigators: One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA 2007;297:1197-1206.